Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Will FDA Allow Zelnorm To Return After 2007 Recall For Safety Reasons?

October 25, 2018 By Law Offices of Thomas J. Lamb, P.A.

We start with this drug safety question: Despite a possible benefit to some limited patient population, is allowing IBS drug Zelnorm back on the market really warranted in view of the potential cardiovascular safety signal, with suicidal ideation and behavior being another issue?

For where things seemed to stand at the conclusion of an October 2018 FDA Advisory Committee meeting about Zelnorm, we get the following form a Medscape news report, “”FDA Panel OKs Tegaserod for IBS With Constipation in Women With Low CV Risk”:

“Given the potential for reintroduction of [Zelnorm] in various subpopulations of interest, elucidating the benefits and risks in the presence of a potential [cardiovascular (CV) as well as suicidal ideation and behavior (SI/B)] safety signal is of particular clinical importance, as patients with IBS-C may have need for additional treatment options but may also be at risk of [adverse events (AEs),” the FDA explains in its briefing document.

“I do think that the CV signal is real, but I think the magnitude of the signal is small,” said temporary voting committee member John Teerlink, MD, professor of medicine, University of California San Francisco; director, Heart Failure, and director, Echocardiography, Section of Cardiology, San Francisco Veterans Affairs Medical Center, California.

On October 17, 2018 the FDA’s Gastrointestinal Drugs Advisory Committee of the US Food and Drug Administration (FDA) voted to recommend that Zelnorm (tegaserod maleate) be approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in women.

We point out that the FDA is not obliged to follow recommendations of its advisory committees but it usually does.

So now we wait to see whether Zelnorm is allowed back on the US market 11 years after the FDA mandated a Zelnorm recall for safety reasons.

[View article at original source]

Filed Under: Unsafe Drugs Tagged With: Cardiovascular death, cardiovascular events, suicidal behavior, suicidal ideation, Zelnorm

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.